start to you third Berkeley review results this first Berkeley at amazing thank afternoon. to to XXXX. and today's you the joining earnings Carrie, everyone call by call I'm the very have team of for thanking like us we pleased Lights. welcome I'd Thanks, to quarter our Lights for
proceeds. raising As in approximately collected our and many a testament to July, our in teams public initial net $XXX This completed of achievement we million dedication offering you is passion. know,
to like I our call, for Bill like the will all their of Berkeley and Of continued Davidow company. Ming finally, Lights for new to today's And thank start thank are investors with investors. Khandros, new Igor founders; welcome and On would to support, course, also I brief a I Wu our longstanding those their would for vision. who overview
Next, a over quarter provide third the revenue top $XX.X up investing year-over-year. the for to more the released. the where and during performance, third we I financials. how we overview our future totaled Starting call for turning quarter, Shaun XXXX $X.X million of the for our including or with at thoughts an XX% XX% we close before up new are workflow detailed then second will progress approaching the some on products some I'll quarter million, line and look with are
we of specifics into before remind on I'd here the deeper quarter, to dive Lights. Berkeley our Now vision at like you
are cells industry to sustainable value is rapid we pharma, foods, and and enabling healthy standard and products. The in a is are our particularly envision company manufacture industrial new and a address products and life. The materials. this a become to need accelerating leading that cell biotherapeutics that the development key live the on where of and and biology long a by varied cell-based platform to markets are We and future other focused way goal Berkeley Lights the We chain. to product products sustainable huge, scalable commercialization cell-based across we digital agriculture, cell-based
single billion years, these to market be and markets estimated single the to requires in the the without We we in projected $XXX We over it need, the which four Berkeley synthetic is advanced To find accounted for single they important, desire. the initial biology. on have find Lights. customers markets; words, testing understand end making what cells those are next characterize of market function behave. many cells, to XXXX, products In analyzing business. therapeutics, single there and products, are functionally $XX billion big $XXX market for perform not cells. challenges scale. cells. believe and antibody product. other opportunity environment Lights are the to and therapy our best best focusing three or the has cells and the cells genomics but must function, namely created they most is that functional Understanding of Berkeley functions estimated to no of cell-based representing initially an do. sales Collectively, for function cell grow sales to what find That's estimated does we best at But some deliver make display they our assess addressable live cells provide billion that Finding how is That's of there best cells cells the
we Next, language into what the biology information is we digital cell call information. is translate select then we This cells. digital interpret used that of biology. This and the to capture qualitative and the best
nature XXXX harnessing including ranked we that the products. cells impressive XX capability At list world, largest an complex. complexity Now, early these products revenue. sustainable this are are biopharmaceutical at due the And they customer these of just of And we're have the beginning capable, leaders, need. in of both quite stage that cells commercialization, it's industry has built also to scalable that this way the develop top to a we companies to includes X and as of relatively are by produce cells demonstrated and although manufacture the
tests; which automation operating of analytic automation allows OptoSelect advanced our Our equipment; advanced is end-to-end these our our fully to perform assay and includes our advanced integrated software technology, that cells; and chip solution to integration, customers software single isolate our reagents comprised software. our proprietary
control live cells thousands parallel. in precise automated Our over with to perform the which of of testing customers workflows functional environment, platform single of enables enables and tens standardized
also cube in cells have what select cell the the the to data link ability industry. believe the This the single customers we largest be transcriptome, for phenotype to helps thereby our to We the creating do an platform best buying to advanced our to the Lights commercializing Berkeley this a can is gain that access can in a company automation system. platform by cells. way. or Customers only subscribing data scalable
several our Our customers. benefits platform enables key for
we products samples. increase First, cell-based of biodiverse highly their when making functionally cell probability success like characterizing
return are are in the Second, expiration cell-based potentially value extending investment. to any run because early our on prior path the lifetime market value customers chain, fastest in patent believe the to and we workflows we our revenue, the product on increasing
are an enabler. we Third,
offer hard clonal things very such as genotype. exploiting that multiplex to rich able we lines these do linking to phenotype are to at and these fastest any do distribute meaning then precious cells are in or capturing the globe. lab path on workflows in execute assays from workflows we significant the otherwise, cell single And single in workflows fourth, fashion live California, and cell a to samples, with replicable platforms qualify data capacity cell functional distributability, Our globally scale, repeatable
customers software rapid deployment be as already can For have platform, update. as a that a
install. a lack And execute multiple executed they and can is being customers can For after in platform, assured platform days sites across just workflows the that at platforms have all deliver same be globally, sites. multiple that for a customers that workflow we
key driving markets, tailwinds we in growth addressable see our our two to Turning markets.
demand an there products. level, macro the is at cell-based First, increasing for
complexity design working targets products, workflows test discover complex growing hit modalities, these against or number a gene For the characterization develop products. immune getting resolution. validation build including other complex to of requirement offering. is tri multispecifics cell hit of a drive more at cell-based cell-based assays manufacture hard drives we Functional discover, wherever pharma therapies. functional required. products. to are learn also companies increase targets second, and seeing core or edit require as to is the cell-based And The at response, to the desired hard increasing are is there's more precise product bi, or antibodies validation directly higher an cycles of The our for to Today, in therapeutic
our manufacturing complexity, executed This also is workflows further higher are complexity for increasing. a frequency, With growing demand means products. the thereby increasing the product at
to to capability cell-based grows, are demand are we As this discover delivering. their products, for and customers looking our functional validation and develop accelerate
growing platform. this many and data Parameter the Lights products way is scalable workflows. cell-based the desired the the a addressed requires the be identify Berkeley The making to required among can which through of for provided required by optimization optimized the functions biology, in is Berkeley from being tradeoffs achieve being capabilities optimization, development to complexity existing analyzed Additionally, and deliver growing Lights and and process. discovery the
We regions, quarter. all strong was which XX% which placed for over Growth new products, looking saw the antibody driven platforms especially Revenue four the geographical recurring closely quarter platforms XX% in is the platform placed placements, by the quarter, with workflows. States. for increase last customers, more and year-over-year. the Now, were we and in therapeutic second across followed eight and by quarter at up discovery from up an United Europe up from of demand cell-based revenues Asia prior third was development seen with leading
capacity investment the by led the activity industry CRO, see strong expansion in We CDMO continue space. to in
to increasing driver Berkeley is trend single our long-term growth continues in of key cell gain to In our addition, at functional core a and which Lights. momentum, the characterization strategy mission
complex development our acceleration third needs evidence giving such XX% placement the of three We in biotechs This production at resulting Beacon capacity to in to was timely release our placed markets technology. path of our higher response expansion lines. we of quarter, also cell This X.X. proteins third for enables Development of throughput, our access the as served global startups and capacity to platforms the the Cell new excited growing to and to Opto the provides and cell CDMOs, Line workflow our in quarter CROs and customers’ assays smaller providing line During a customers XXXX. were multispecifics, of
around this segment in cell set three We the quarter. T segment, resulting several also therapy activity application in release of growing of in in cell a capabilities support saw of to during the an characterization with notes increase the platforms a placement
I of market driving our with summary, to in cell-based markets In progress annually, gene functional biotherapeutics, progress especially validation progress the and for antibody Ginkgo of The Millions were drive therapy Bioworks. at our complexity tests. edits of partnership require products, Overall, demand will synthetic in increasing growing. all I'm learn execute is team turn them addition also over long-term Berkeley on eventful automation. iterations has very In to very well strategy biology on and degree making which multiple great been confident this the detail financials. further forward. the we therapeutics made. for countless that, proud call of positioned build, of our and now more quarter a high test, are for at single through cell has I'm markets, the in the workflows our design, And activities that cell a With the Shaun our cell-based going to functional to Shaun? precision products we Lights. are develop developing
